In 2026 two randomised controlled trials were published testing fisetin alongside interval resistance and aerobic training in sedentary men with obesity [1][2]. Between them they report improvements in inflammatory markers, insulin resistance, adipokines and lipids. Counted by outcomes measured, it is one of the larger sets of human data fisetin has.
It is also almost certainly one trial reported twice, and reading it as two independent studies would substantially overstate the evidence. That is worth establishing before looking at any of the numbers.
Key Takeaways
- Two 2026 randomised controlled trial reports tested fisetin at 200 mg per day with twelve weeks of interval resistance and aerobic training in men with obesity.
- The two papers share design, dose, training protocol and arm labels, and are almost certainly one trial reported across two outcome panels.
- Significant group by time interactions were found for Maresin-1, IL-6, TNF-alpha, fasting glucose, insulin and HOMA-IR.
- The combined training plus fisetin arm showed the largest reductions in asprosin, down 60.71%, and MCP-1, down 46.50%.
- Most of the effect appears in arms that include exercise, and the trial does not isolate fisetin as the driver.
Important: This article describes short-term biomarker outcomes in sedentary men with obesity and is not medical advice. Fisetin has not been shown to prevent or treat obesity, diabetes or cardiovascular disease. Most of the improvements reported occurred in groups that exercised. Speak to a doctor before starting a supplement or a new exercise programme, particularly if you have a metabolic condition or take prescription medication.
Why these are probably one trial
Set the two papers side by side. Both are twelve-week, four-arm, parallel-group randomised controlled trials in men with obesity, and the adipokine paper further describes its trial as double-blind and its participants as sedentary. Both use fisetin at 200 mg per day. Both use the same training protocol: eight resistance exercises at 60% of one-rep maximum with active rest, followed by staged aerobic bouts at 50% to 70% of maximum heart rate. Both use the same four arm labels, control-placebo, fisetin alone, training-placebo and training plus fisetin [1][2].
The differences are the outcome panels and the completer counts. One reports 44 men completing and measures Maresin-1, IL-6, TNF-alpha, fasting glucose, insulin and HOMA-IR [1]. The other reports 60 men completing and measures asprosin, MCP-1, adiponectin, leptin and lipids [2].
The most straightforward explanation is one trial split across two papers by outcome panel, with different numbers of participants having usable data for each set of assays. Presenting them as two independent replications would be a misrepresentation, because a finding repeated in the same participants is not a replication. Neither paper is doing anything improper by publishing this way; the error would be in how the two are counted.
The inflammation and insulin results
Significant group by time interactions were reported for Maresin-1 at p = 0.034, IL-6 at p = 0.001, TNF-alpha at p = 0.001, fasting blood glucose at p = 0.001, insulin at p = 0.001 and HOMA-IR at p = 0.001 [1]. Maresin-1, a specialised pro-resolving mediator, increased in the training-placebo and training-plus-fisetin groups.
IL-6 decreased in the training, training-plus-fisetin and fisetin-only groups, the last at p = 0.013. TNF-alpha decreased in all three intervention arms at p = 0.002. Fasting glucose, insulin and HOMA-IR decreased significantly in all active arms at p = 0.003, with the largest reductions in the training-plus-fisetin group [1].
The IL-6 and TNF-alpha results in the fisetin-only arm are the ones to notice, because they are the only place in this trial where fisetin without exercise moved a marker on its own. Everywhere else the effect is either exercise alone or the combination.
The adipokine and lipid results
The companion paper reported large effects on asprosin, F(3, 55) = 36.047, p < 0.001, and MCP-1, F(3, 55) = 29.570, p < 0.001 [2]. The training-plus-fisetin group showed the largest reductions in both, asprosin down 60.71% and MCP-1 down 46.50%.
Adiponectin rose significantly in the training-placebo group by 29.38% and the training-plus-fisetin group by 27.67%. Leptin change reached significance only in the training-plus-fisetin group against placebo at p = 0.049. For lipids, the training-plus-fisetin group improved LDL-C, triglycerides and total cholesterol at p < 0.001 while HDL-C rose, and post hoc tests confirmed differences for both training arms against placebo [2].
The placebo group is easy to overlook and worth stating: over the same twelve weeks it deteriorated, with LDL-C rising at p = 0.027 and HDL-C falling at p = 0.006 [2]. Part of the apparent benefit in the active arms is the placebo group getting worse, which is a normal feature of sedentary control groups and a reason to read percentage differences carefully.
What the trial does not establish
It does not isolate fisetin as the driver. Adiponectin rose almost as much with training and placebo as with training and fisetin, and the largest changes throughout are in arms that include exercise. The most defensible reading is that training does the heavy lifting and fisetin adds something on top of it for some markers.
The authors of the adipokine paper add their own limitation, noting that direct mechanistic assays were not conducted and that implications about asprosin as a modulator of metabolic risk remain hypothetical [2]. That caution belongs in any summary of this work.
The population is also narrow: sedentary men with obesity. Nothing here extends to women, to people of normal weight, or to older adults, and the fisetin dose of 200 mg per day sits between the 100 mg used in other human trials [3] and the pulsed senolytic doses discussed elsewhere. These were also outcome markers over twelve weeks, not long-term health events. For the broader picture, see the muscle senescence research on fisetin and exercise and what is known about blood sugar and insulin.
Common questions
Does fisetin help with weight loss?
In this trial, weight loss occurred in the fisetin, training-placebo and training-plus-fisetin groups compared with placebo, but body mass index reached significance only in the combined training and fisetin group [2]. Exercise is doing most of the work in these results.
Are these two separate trials confirming each other?
Almost certainly not. Both are twelve-week four-arm trials in men with obesity using 200 mg of fisetin daily and an identical training protocol, differing mainly in outcome panel and completer count, 44 versus 60 [1][2]. They are best read as one trial reported twice.
Did fisetin do anything without exercise?
In the fisetin-only arm, IL-6 fell at p = 0.013 and TNF-alpha fell as part of a significant reduction across all intervention groups at p = 0.002 [1]. That is the clearest signal for fisetin alone, and it is limited to inflammatory markers.
What is asprosin and why does it matter here?
Asprosin is a hormone associated with glucose regulation and metabolic risk. The combined training and fisetin group showed a 60.71% reduction [2], though the authors note no direct mechanistic assays were done, so its role remains hypothetical.
Is 200 mg per day the right fisetin dose?
It is the dose this trial used. Human fisetin trials have not converged: one registered protocol uses 100 mg daily in adults aged 50 and over [3], and other work uses far larger pulsed doses. There is no established optimal dose.
Do these results apply to women or to people who are not obese?
No. Both papers studied men with obesity, so the findings cannot be extended to women, to people of normal weight, or to other age groups without trials in those populations.
References
- 12-weeks fisetin supplementation and interval resistance with aerobic training: changes in Maresin-1 and inflammatory markers in men with obesity: a randomized controlled trial. J Int Soc Sports Nutr (2026). PMID 42218768
- The Effects of Interval Resistance-Aerobic Training and Fisetin Supplementation on Asprosin and Selected Adipokines in Obese Men: A Double-Blind Randomized Control Trial. Nutrients (2026). PMID 41683255
- Low-Dose Fisetin Supplementation and Its Association With Chronic Inflammation in Middle-Aged and Older Adults: Study Protocol for a Triple-Blind, Randomised, Placebo-Controlled Trial. Basic Clin Pharmacol Toxicol (2026). PMID 42633989
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.